Diabetic nephropathy an update;Néphropathie diabétique

Revue Medicale Suisse

Volumn 8, Issue 330, 2012, Pages 473-479

  Gariani, K ^a   De Seigneux, S ^b   Pechere Bertschi A ^c   Philippe, J ^d   Martin, P Y ^b  

^a Service de Medecine Interne Generale   (Switzerland)

^b Service de Nephrologie   (Switzerland)

^c CHUV   (Switzerland)

^d HUG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CASE REPORT; DIABETIC NEPHROPATHY; HUMAN; REVIEW; BIOLOGICAL MODEL; DRUG ANTAGONISM; ENDOCRINOLOGY; METHODOLOGY; RISK FACTOR;

ADVANCED GLYCATION END PRODUCT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DIABETIC NEPHROPATHIES; ENDOCRINOLOGY; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MODELS, BIOLOGICAL; RISK FACTORS;

EID: 84860348701     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Ritz E. Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care 2011;34(Suppl. 2):S330-4.
2. Ponte B, Pruijm M , Martin PY, et al. Prevalence of chronic kidney disease in the adult population of Lausanne-Switzerland. J Am Soc Nephrol 2011;22:abstract.
3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes : Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
4. Gross JL, de Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy : Diagnosis, prevention, and treatment. Diabetes Care 2005;28:164-76.
5. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care 2004;27(Suppl. 1): S79-83.
6. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 2008;4:444-52.
7. Brosius FC. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropaty. Rev Endocr Metab Disord 2008;9:245-54.
8. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-12.
9. The DCCT/EDIC research group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;365:2366-76.
10. KDOQI. Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(Suppl. 2):S12-154.
11. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34 (Suppl. 1):S11-6.
12. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes : Systematic review and meta-analysis. Lancet 2005;366:2026-33.
13. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
14. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16: 489-95.
15. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of heart and renal protection) : A randomised placebo-controlled trial. Lancet 2011;377:2181-92.
16. Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev 2007;(4):CD002181.
17. Chuahirun T, Simoni J, Hudson C, et al. Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes. Am J Medical Sciences 2004;327:57-67.
18. De Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) : A randomized controlled trial. Lancet 2010;376:1543-51.
19. Kim MJ, Frankel AH, Donaldson M, et al. Oral cholecalciferol decreases albuminuria and urinary TGF-b1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int 2011;80:851-60.
20. Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365:327-36.
21. Williams ME. Clinical studies of advanced glycation end Product inhibitors and diabetic kidney disease. Curr Diab Rep 2004;4:441-6.
22. Chen JL, Francis J. Pyridoxamine, advanced glycation inhibition, and diabetic nephropathy. J Am Soc Nephrol 2012;23:6-8.
23. Lewis EJ, Lewis JB, Greene T, et al. Collaborative study group. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: A randomized controlled trial. Am J Kidney Dis 2011;58:729-36.
24. Wolfe R, Reutens A, Ivory S, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 2011;23:123-30.
25. Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21:527-35.